We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Oct 20
Branaplam is an orally administered small molecule RNA splicing modulator, currently being studied for the treatment of spinal…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Oct 20
The acquisition would add Disarm's axonal degeneration therapies to expand Lilly's pain and neurodegeneration capabilities
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Oct 20
Through the acquisition, Bristol Myers will benefit from MyoKardia’s investigational cardiovascular medicine mavacamten for obstructive hypertrophic cardiomyopathy (HCM)…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Sep 20
GSK said that the FDA approval makes Nucala the first and only approved biologic for the treatment of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Sep 20
Roche paid an upfront payment of €380m to the Inflazome shareholders, and are also eligible to receive additional…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Sep 20
The deal will benefit Gilead with Trodelvy (sacituzumab govitecan-hziy), an advanced Trop-2 directed antibody-drug conjugate, developed by Immunomedics
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Sep 20
Takeda is expected to receive around $562m in an upfront payment, subject to customary legal and regulatory closing…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Aug 20
The sale of consumer health care business will further strengthen Takeda’s focus on five key business areas, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Aug 20
Kesimpta is indicated for relapsing forms of MS (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Aug 20
The acquisition will enable J&J’s pharmaceutical business Janssen to expand its operations in immune-mediated diseases and autoantibody-driven diseases
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates